Redo TAVI: how to treat different TAVI platforms when they fail?

In this EuroPCR 2025 interview, Tanja Rudolph, Dan Blackman, and Radoslaw Parma take a deep dive into the current understanding of redo TAVR.

Together, they address the main challenges faced in repeat procedures—chiefly, the risk of coronary obstruction and the importance of preserving coronary access, alongside strategies for optimising hemodynamics in the presence of higher residual gradients.

The conversation highlights the influence of the original TAVR device on outcomes, and explains why comprehensive CT screening is now seen as a cornerstone of safe and effective planning.

Finally, the discussion turns to the available clinical evidence and what further data can be expected soon.

This interview was filmed at EuroPCR 2025: see more videos here.